Insider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) Insider Sells 4,078 Shares of Stock

Sera Prognostics, Inc. (NASDAQ:SERA) insider Paul Kearney sold 4,078 shares of Sera Prognostics stock in a transaction on Monday, November 11th. The shares were sold at an average price of $7.32, for a total value of $29,850.96. Following the completion of the sale, the insider now owns 176,889 shares in the company, valued at $1,294,827.48. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Sera Prognostics Price Performance

SERA opened at $7.24 on Wednesday. Sera Prognostics, Inc. has a 12 month low of $1.65 and a 12 month high of $12.35. The business has a fifty day moving average price of $7.41 and a 200 day moving average price of $7.65.

Sera Prognostics (NASDAQ:SERA) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.09 million. During the same period in the prior year, the company posted ($0.23) earnings per share. Research analysts anticipate that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

Hedge Funds Weigh In On Sera Prognostics

A number of large investors have recently modified their holdings of the business. RA Capital Management L.P. acquired a new stake in Sera Prognostics during the 1st quarter valued at $18,420,000. AWM Investment Company Inc. raised its position in shares of Sera Prognostics by 56.0% in the 1st quarter. AWM Investment Company Inc. now owns 584,664 shares of the company’s stock worth $5,320,000 after buying an additional 209,762 shares during the period. Bank of New York Mellon Corp raised its position in Sera Prognostics by 100.2% in the second quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock valued at $892,000 after purchasing an additional 75,441 shares during the period. Ballentine Partners LLC purchased a new position in Sera Prognostics in the second quarter valued at about $294,000. Finally, Twelve Points Wealth Management LLC purchased a new position in Sera Prognostics in the second quarter valued at about $257,000. 54.64% of the stock is owned by hedge funds and other institutional investors.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.